Please login to the form below

Not currently logged in
Email:
Password:

Cancer detection breath test prototype

A tool to detect lung, colorectal, breast and prostate cancer could be developed based on positive results from a small trial with a prototype

Researchers from Israel have developed a prototype tool to detect cancer in the breath, according to a study published today in the British Journal of Cancer.

The researchers tested the ability of a nanosensor array to distinguish between volatile organic compounds (VOCs) in the exhaled alveolar breath of 177 patients. The patients in the trials were either healthy or had breast, lung, colon or prostate cancer. 

They found that the nanosensor array was not only able to determine which subjects had cancer but was also able to detect the type of cancer with a high degree of sensitivity. The results were not affected by biological or lifestyle factors, such as smoking.

Following these positive results, the researchers have suggested that it may one day be possible to develop an inexpensive, non-invasive, portable, easy-to-use device that would be used as a diagnostic tool in a primary care setting. Early detection through a simple, inexpensive tool would improve the survival rate of cancer. It would also be possible to use the suggested tool to monitor the effectiveness of treatment in cancer patients and detect relapses.

11th August 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

Peter Jackson
Rethinking our approach to infectious disease preparedness
The importance of long-term strategic investment to prepare for the next threat that emerges...
New from the PhRMA: Diversity in clinical trials principles summarised
In November 2020, PhRMA announced the first-ever, industry-wide principles on clinical trial diversity. The principles were approved by the PhRMA Boards of Directors and will take effect in April 2021....
New from the FDA: Diversity in clinical trials guidance summarised
In November 2020, the FDA released guidance to enable greater diversity in clinical trials through changes to eligibility criteria, enrolment practices, and trial designs....

Infographics